Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil

Clinical trials have shown the benefits of acetylcholinesterase inhibitors, such as donepezil and galantamine, and an N-methyl-D-aspartate receptor antagonist, memantine, in patients with Alzheimer’s disease (AD). However, little is known regarding the effects of switching from donepezil 5 mg/day to...

Descripción completa

Detalles Bibliográficos
Autores principales: Kano, Osamu, Ito, Hirono, Takazawa, Takanori, Kawase, Yuji, Murata, Kiyoko, Iwamoto, Konosuke, Nagaoka, Tetsuro, Hirayama, Takehisa, Miura, Ken, Nagata, Riya, Kiyozuka, Tetsuhito, Aoyagi, Jo, Sato, Ryuta, Eguchi, Teruo, Ikeda, Ken, Iwasaki, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575212/
https://www.ncbi.nlm.nih.gov/pubmed/23431041
http://dx.doi.org/10.2147/NDT.S40682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575212/
https://www.ncbi.nlm.nih.gov/pubmed/23431041
http://dx.doi.org/10.2147/NDT.S40682

Ejemplares similares